Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSV | O60911 | 2/20 | 0.42 |
| ▸ | CTSL | P07711 | 2/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.41 |
| ▸ | STING1 | Q86WV6 | 9/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.38 |
| ▸ | ASPH | Q12797 | 1/20 | 0.37 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.37 |
| ▸ | PYGL | P06737 | 1/20 | 0.37 |
| ▸ | ACLY | P53396 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2081121 | 0.86 | ROCK2 (0.41) | CTSVCTSLKEAP1NFE2L2STING1 | |
| SCHEMBL16364784 | 0.85 | STING1 (0.43) | KEAP1NFE2L2STING1MAPTKDM4E | |
| SCHEMBL16004173 | 0.85 | KCNK2 (0.49) | CTSVCTSLKEAP1NFE2L2STING1 | |
| SCHEMBL30240184 | 0.85 | STING1 (0.43) | KEAP1NFE2L2STING1MAPTKDM4E | |
| SCHEMBL22045554 | 0.85 | MAPT (0.46) | KEAP1NFE2L2STING1MAPTKDM4E | |
| SCHEMBL29133155 | 0.84 | MAPT (0.45) | MAPTKDM4EALDH1A1NPC1POLB | |
| Hydrochloric Acid SCHEMBL21988698 | 0.83 | MAPT (0.45) | KEAP1NFE2L2STING1MAPTKDM4E | |
| Hydrochloric Acid SCHEMBL21988903 | 0.83 | KCNK2 (0.48) | CTSVCTSLKEAP1STING1MAPT | |
| Hydrochloric Acid SCHEMBL15994581 | 0.83 | KCNK2 (0.48) | CTSVCTSLKEAP1STING1MAPT | |
| Hydrochloric Acid SCHEMBL16320375 | 0.83 | STING1 (0.43) | KEAP1NFE2L2STING1MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190152979-A1 | SUBSTITUTED PYRAZOLOQUINAZOLINONES AND PYRROLOQUINAZOLINONES AS ALLOSTERIC MODULATORS OF GROUP II METABOTROPIC GLUTAMATE RECEPTORS | DOMAIN THERAPEUTICS (FR) | 2019-05-23 | — | — | US | disclosed |
| US-10221179-B2 | Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors | DOMAIN THERAPEUTICS (FR) | 2019-03-05 | — | — | US | disclosed |
| US-20170305913-A1 | SUBSTITUTED PYRAZOLOQUINAZOLINONES AND PYRROLOQUINAZOLINONES AS ALLOSTERIC MODULATORS OF GROUP II METABOTROPIC GLUTAMATE RECEPTORS | DOMAIN THERAPEUTICS (FR) | 2017-10-26 | — | — | US | disclosed |
| EP-3197897-A1 | SUBSTITUTED PYRAZOLOQUINAZOLINONES AND PYRROLOQUINAZOLINONES AS ALLOSTERIC MODULATORS OF GROUP IIMETABOTROPIC GLUTAMATE RECEPTORS | Domain Therapeutics (FR) | 2017-08-02 | — | — | EP | disclosed |
| WO-2016046404-A1 | SUBSTITUTED PYRAZOLOQUINAZOLINONES AND PYRROLOQUINAZOLINONES AS ALLOSTERIC MODULATORS OF GROUP IIMETABOTROPIC GLUTAMATE RECEPTORS | DOMAIN THERAPEUTICS (FR) | 2016-03-31 | — | — | WO | disclosed |
| EP-3000814-A1 | Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors | Domain Therapeutics (FR) | 2016-03-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10221179-B2 | Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors | GRM1, GRM2, GRIN1 | CTSV 4727/4885CTSL 4637/4885KEAP1 1818/4885 |
| US-20170305913-A1 | SUBSTITUTED PYRAZOLOQUINAZOLINONES AND PYRROLOQUINAZOLINONES AS ALLOSTERIC MODULATORS OF GROUP II METABOTROPIC GLUTAMATE RECEPTORS | GRM1, GRM2, GRIN1 | CTSV 4727/4885CTSL 4637/4885KEAP1 1818/4885 |
| US-20190152979-A1 | SUBSTITUTED PYRAZOLOQUINAZOLINONES AND PYRROLOQUINAZOLINONES AS ALLOSTERIC MODULATORS OF GROUP II METABOTROPIC GLUTAMATE RECEPTORS | GRM1, GRM2, GRIN1 | CTSV 4686/4885CTSL 4603/4885KEAP1 1850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.